Volume 32, Issue 1 (2-2018)                   Med J Islam Repub Iran 2018 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Hameed A, Ali J, Munawar K, Arshad F, Badar F, Siddiqui N. Characteristics and outcomes of patients with multiple myeloma : Data from a developing country . Med J Islam Repub Iran. 2018; 32 (1) :1-5
URL: http://mjiri.iums.ac.ir/article-1-4509-en.html
Department of Medical Oncology, Shaukat Khanum Cancer Hospital and Research Centre, Pakistan. , hamiid34@gmail.com
Abstract:   (1082 Views)

Background: Multiple myeloma (MM) is a plasma cell disorder characterized by presence of monoclonal protein in serum or urine or both, increased bone marrow plasma cells, osteolytic lesion, hypercalcemia, and anemia. Several combination regimens are commonly recommended for treatment of multiple myeloma. The present study aimed at determining the characteristics and outcomes of patients with multiple myeloma treated at our centre.
   Methods: During July 2012 and December 2015, all patients with proven diagnosis of MM were included in this study. Data were collected from hospital information system. The characteristics and outcomes of all patients were analyzed. Progression- free survival and overall survival of patients were also estimated. Kaplan-Meier curves and Log-rank test were applied and SPSS Version19 was used for data analysis.
   Results: A total of 82 patients, with the median age of 51 years (Range: 23-64 yrs.) were available for final analysis. The number of patients with IgG and IgA type was 48 (58.5%) and 15(18.3%), respectively. There were 7 (8.5%) patients with non-secretory type. Most of the patients (n= 59; 71.9%) were treated with CTD regimen and 13 (15.8%) received bortezomib-based treatment. The median progression-free survival time was 30 months, and overall survival time was 48 months. The cumulative probability of survival at 36 months was 85%.
   Conclusion: Based on our results, the onset of multiple myeloma occurs in relatively younger age groups.  A small number of patients received bortezomib due to cost issues. PFS and OS in our study were comparable with published literature.
 

Full-Text [PDF 431 kb]   (674 Downloads)    
Type of Study: Original Research | Subject: Hematology

Add your comments about this article : Your username or Email:
CAPTCHA code

Send email to the article author